Oral News and Research

RSS

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.

20 Nov 2010

NexACT technology improves oral delivery of five small molecule drugs

Apricus Biosciences, Inc., today announced data from animal studies showing that the NexACT technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption.

20 Nov 2010

State roundup: California PPOs 'low marks'; Geriatric nursing; Physician shortages

News outlets covered a range of developments including workforce issues in Minnesota and California, and a Kentucky order for insurers to provide child-only policies.

19 Nov 2010

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.

19 Nov 2010

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cyclacel Pharmaceuticals, Inc. announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of myelodysplastic syndromes (MDS) will be presented at a poster presentation during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, on Saturday, December 4, 2010.

19 Nov 2010

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ZIOPHARM Oncology, Inc. announced today important new preclinical data on the efficacy of darinaparsin (ZinaparTM, or ZIO-101) in various solid tumor models delivered at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany.

19 Nov 2010

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Cough medicine could be used as way of predicting how well individual patients metabolise tamoxifen used in the treatment of their breast cancer, according to new research presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin today

19 Nov 2010

Caprini Risk Model helps predict VTE risk in patients undergoing plastic surgery

Patients undergoing plastic or reconstructive surgery should receive a risk assessment before their procedure to predict whether they'll develop potentially fatal blood clots in the legs or lungs, according to research at the University of Michigan Medical School. Researchers also found that 1 in 9 patients at highest risk based on that assessment will develop clots if not given clot-preventing medications after surgery.

19 Nov 2010

DCR to present data on DaVita Cathaway program at ASN Annual Meeting

DaVita Clinical Research, a provider of clinical research and diagnostic laboratory services, announced today that 56 posters and five oral presentations will be presented by the Company's unsurpassed renal experts at the 43rd American Society of Nephrology (ASN) Annual Meeting and Scientific Exposition from November 16 - 21, 2010, at the Colorado Convention Center located in Denver, Colorado.

19 Nov 2010

GRAVITAS Trial finds high dose of clopidogrel does not reduce risk of ischemic events

Accumetrics, Inc., developer and marketer of the VerifyNow System, today announced that the GRAVITAS (Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety) Trial found that in patients with high residual platelet reactivity, doubling the maintenance dose of clopidogrel did not reduce the risk of further ischemic events after percutaneous coronary intervention (PCI).

19 Nov 2010

Robot-assisted endoscope removes salivary stone, repairs duct

Dr. Rohan Walvekar, Assistant Professor of Otolaryngology Head and Neck Surgery, Director of Clinical Research and the Salivary Endoscopy Service at LSU Health Sciences Center New Orleans, has reported the first use of a surgical robot guided by a miniature salivary endoscope to remove a 20mm salivary stone and repair the salivary duct of a 31-year-old patient.

19 Nov 2010

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

Oncolytics Biotech Inc. announced today that the Children's Oncology Group (COG) intends to conduct a Phase I trial of REOLYSIN in combination with cyclophosphamide in pediatric patients with relapsed or refractory solid tumors.

19 Nov 2010

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced four key belinostat data presentations at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

19 Nov 2010

Cholera confirmed in Florida woman who traveled to Haiti

"The first known case of cholera in the United States linked to the outbreak in Haiti was confirmed Wednesday by health officials who said a southwest Florida woman contracted the disease while visiting family in a region at the heart of Haiti's epidemic," the New York Times reports.

19 Nov 2010

Gene transfer reduces and stabilizes plaque and decreases inflammation

A plaque-fighting gene - studied in various forms by researchers at the Cedars-Sinai Heart Institute for 18 years - has now been transferred intravenously to lab mice bred to model atherosclerosis (clogged arteries) in humans. Studies show the gene transfer reduced and stabilized plaque and decreased inflammation, key factors in cutting the risk of heart disease.

18 Nov 2010

Cholera case confirmed in Dominican Republic; Haitian protestors blame U.N. peacekeeping troops for cholera outbreak

Officials on Tuesday said they had confirmed the first case of cholera in Haiti's neighbor, the Dominican Republic, the Associated Press/Forbes reports

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

VX-770 drug candidate improves lung function in people with cystic fibrosis

In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.

18 Nov 2010

Food allergies may lead to 'kissing' allergies

Even brushing your teeth or waiting hours after eating may not prevent some partners of people with food and medicine allergies from triggering an allergic reaction through a kiss, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov.11-16.

17 Nov 2010

Oral News and Research

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

NexACT technology improves oral delivery of five small molecule drugs

State roundup: California PPOs 'low marks'; Geriatric nursing; Physician shortages

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Caprini Risk Model helps predict VTE risk in patients undergoing plastic surgery

DCR to present data on DaVita Cathaway program at ASN Annual Meeting

GRAVITAS Trial finds high dose of clopidogrel does not reduce risk of ischemic events

Robot-assisted endoscope removes salivary stone, repairs duct

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting

Cholera confirmed in Florida woman who traveled to Haiti

Gene transfer reduces and stabilizes plaque and decreases inflammation

Cholera case confirmed in Dominican Republic; Haitian protestors blame U.N. peacekeeping troops for cholera outbreak

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

VX-770 drug candidate improves lung function in people with cystic fibrosis

Food allergies may lead to 'kissing' allergies

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News